Home・Список акций・Viking Therapeutics Inc

Viking Therapeutics Inc

Закрыт

СекторЗдравоохранение

32.81 0.71

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

32.47

Макс.

33.51

Ключевые показатели
By Trading Economics
Доход	30M -128M
Прибыль на акцию	-1.1
Сотрудники	65
EBITDA	30M -128M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+182.37% upside

Дивиденды
By Acuity
Следующий отчет о доходах	21 окт. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-245M 3.8B
Предыдущая цена открытия	32.1
Предыдущая цена закрытия	32.81

Новостные настроения

By Acuity

50%

175 / 340 Рейтинг в Healthcare

Viking Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3 авг. 2026 г., 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31 июл. 2026 г., 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30 июл. 2026 г., 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29 июл. 2026 г., 23:21 UTC

Social Media

News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28 июл. 2026 г., 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27 июл. 2026 г., 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

25 июл. 2026 г., 00:01 UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

24 июл. 2026 г., 21:01 UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

23 июл. 2026 г., 23:46 UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

22 июл. 2026 г., 23:36 UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Сравнение c конкурентами

Изменение цены

Viking Therapeutics Inc Прогноз

Целевая цена

By TipRanks

182.37% рост

Прогноз на 12 месяцев

Средняя 92.08 USD 182.37%

Максимум 114 USD

Минимум 70 USD

Основано на мнении 14 аналитиков Wall Street, спрогнозировавших целевые цены для Viking Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

14 ratings

Покупка

Удержание

Продажа

Основано на мнении 14 аналитиков, присваивавших рейтинги акциям Viking Therapeutics Inc – Данные за последние 3 месяца.

Настроения

By Acuity

175 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.